Skip to content

The impact of real-world data in gaining access to the European orphan drugs market. 

Gain key insights: RWD’s role in successful drug launches

Europe presents a significant opportunity for international biotech’s developing and commercialising rare and orphan medicines. 

With the EMA’s increasing focus on Real-World Data in its regulatory processes, there are several ways in which applying it can help speed up access to the European market.

This essential guide covers:

  • What is Real-World Data and how it is used in the pharmaceutical industry
  • How RWD can help to speed up access to European markets
  • The importance of RWD in regulatory and HTA submissions
  • RWD as a strategic tool for pricing and reimbursement negotiations
  • The advantages of RWD over controlled clinical trial data
  • The EMA’s recognition of RWD

Download this exclusive guide to discover how Real-World Data can improve your chance of success in this complex market.

Consent(Required)
This field is for validation purposes and should be left unchanged.